CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 72 enrolled
Drug / intervention
Bevacizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02873962
NCT02873962Phase 2Active
CompareCT.gov

A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

Dana-Farber Cancer Institute·interventional·Posted Aug 22, 2016·Updated Apr 1, 2026

In Brief

A Phase 2 clinical trial evaluating Bevacizumab, Nivolumab, and 1 other intervention for Peritoneal Cancer and 2 related conditions. Active but no longer recruiting, targeting 72 participants across 3 sites.

Detailed Summary

This research study is evaluating three drugs called Nivolumab, Bevacizumab, and Rucaparib as a possible treatment for relapsed Relapsed Ovarian, Fallopian Tube Or Peritoneal Cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeritoneal Cancer, Ovarian Cancer, Fallopian Tube Cancer
CountriesUnited States
CollaboratorsBristol-Myers Squibb, Clovis Oncology, Inc.

Timeline

Phase 2Active
20172018201920202021202220232024202520262027
First PostedAug 22, 2016
Enrollment StartNov 10, 2016
Primary CompletionFeb 1, 2025
Study CompletionJan 1, 2027
TodayJul 2, 2026
Enrollment to primary: 8.2 yearsPosted 9.9 years ago

Interventions

Bevacizumabdrug

* Bevacizumab will be given intravenously at a pre-determined dosage * One dose reduction will be allowed for Bevacizumab

Nivolumabdrug

* Nivolumab injection is to be administered as an IV infusion at a pre-determined dosage. * No dose reductions or escalations will be allowed for Nivolumab

Rucaparibdrug

* Rucaparib will be taken orally twice daily on days 1-14 at a pre-determined dosage. * Up to three dose reductions will be allowed for Rucaparib (depending on cohort).